Is Stryker Corporation (NYSE:SYK) Potentially Undervalued?

Stryker Corporation (NYSE:SYK) saw significant share price movement during recent months on the NYSE, rising to highs of US$400 and falling to the lows of US$355. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Stryker's current trading price of US$390 reflective of the actual value of the large-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Stryker’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

Check out our latest analysis for Stryker

Advertisement

What Is Stryker Worth?

The stock seems fairly valued at the moment according to our valuation model. It’s trading around 18.53% above our intrinsic value, which means if you buy Stryker today, you’d be paying a relatively fair price for it. And if you believe the company’s true value is $329.28, then there isn’t really any room for the share price grow beyond what it’s currently trading. In addition to this, Stryker has a low beta, which suggests its share price is less volatile than the wider market.

What does the future of Stryker look like?

earnings-and-revenue-growth
NYSE:SYK Earnings and Revenue Growth February 26th 2025

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. With profit expected to grow by 58% over the next couple of years, the future seems bright for Stryker. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What This Means For You

Are you a shareholder? SYK’s optimistic future growth appears to have been factored into the current share price, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the track record of its management team. Have these factors changed since the last time you looked at the stock? Will you have enough conviction to buy should the price fluctuates below the true value?

Are you a potential investor? If you’ve been keeping an eye on SYK, now may not be the most optimal time to buy, given it is trading around its fair value. However, the positive outlook is encouraging for the company, which means it’s worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. For example - Stryker has 3 warning signs we think you should be aware of.

If you are no longer interested in Stryker, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NYSE:SYK

Stryker

Operates as a medical technology company.

Adequate balance sheet average dividend payer.

Advertisement

Weekly Picks

JO
Jolt_Communications
MYSE logo
Jolt_Communications on Myseum ·

The Future of Social Sharing Is Private and People Are Ready

Fair Value:US$7.9576.7% undervalued
35 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
TO
Tokyo
ASML logo
Tokyo on ASML Holding ·

EU#3 - From Philips Management Buyout to Europe’s Biggest Company

Fair Value:€1.31k9.0% undervalued
30 users have followed this narrative
4 users have commented on this narrative
11 users have liked this narrative
YI
BKNG logo
yiannisz on Booking Holdings ·

Booking Holdings: Why Ground-Level Travel Trends Still Favor the Platform Giants

Fair Value:US$5.47k15.0% undervalued
7 users have followed this narrative
0 users have commented on this narrative
4 users have liked this narrative
CO
composite32
SHEL logo
composite32 on Shell ·

A fully integrated LNG business seems to be ignored by the market.

Fair Value:UK£36.122.7% undervalued
39 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative

Updated Narratives

RE
PROX logo
RecMag on Proximus ·

Proximus: The State-Backed Backup Plan with 7% Gross Yield and 15% Currency Upside.

Fair Value:€17.1354.8% undervalued
37 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
CO
composite32
SGRO logo
composite32 on SEGRO ·

SEGRO's Revenue to Rise 14.7% Amidst Optimistic Growth Plans

Fair Value:UK£9.3918.8% undervalued
6 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AL
alex30free
BEIJ B logo
alex30free on Beijer Ref ·

The Green Consolidator

Fair Value:SEK 128.821.0% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

WE
WealthAP
PYPL logo
WealthAP on PayPal Holdings ·

The "Sleeping Giant" Stumbles, Then Wakes Up

Fair Value:US$8249.1% undervalued
85 users have followed this narrative
6 users have commented on this narrative
35 users have liked this narrative
OO
NEO logo
OOO97 on Neo Performance Materials ·

Undervalued Key Player in Magnets/Rare Earth

Fair Value:CA$25.3320.9% undervalued
75 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$253.0228.7% undervalued
1049 users have followed this narrative
6 users have commented on this narrative
31 users have liked this narrative

Trending Discussion

HE
Hemingway
AEVA logo
Hemingway on Aeva Technologies ·

NVDA+AEVA Agreement is a game changer for the AEVA stock even though it is just a partnership and does not have a roll out until 2028 (which means receivables as early as 2027, I would imagine) This agreement effectively moves the goal posts of profitability for AEVA much closer since this is in addition to the recent Forterra agreement, as well as the (previously announced) European carmaker agreement (which is believed to be Mercedes-Benz and estimated to be worth at least 1 billion in sales alone) Underneath all of this, AEVA has a pre-existing agreement with Daimler Truck. So business seems to be booming, especially with really big name brands…which tends to bring in even more brand names (and thus more agreements/contracts/announcements, etc). This dynamic often creates more coverage from analysts (often with upside stock initial coverage) that I believe will be occurring over the next 3 to 6 months (as professional traders/analysts often research for 2 to 3 months before initiating coverage of a new issue). I also feel that the above momentum increases the likelihood that companies that do not currently utilize 4G LIDAR technology might consider buying AEVA outright. Realistically, even with a substantial premium to the current stock price, the cost of AEVA would be a rounding error for the likes of a company such as Tesla, and certainly would allow them to maintain their technological edge as the competition for self-driving vehicles continues to heat up. However, I think it is equally possible for NVidea to decide to lock-in the AEVA technology for their upcoming autonomous hardware/software package by buying them outright. Obviously, the above factors and recent activity in the AEVA stock are cause for optimism. Of course, this all just one opinion , so please do your own due diligence. Disclaimer: I/We DO trade in this stock from time to time and I/we may (or may not have) a position currently, so again, please do your own due diligence.

0
|
0
US
AVGO logo
User on Broadcom ·

Net here,remains to be seen!

0
|
0
Advertisement